{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T06:22:38Z","timestamp":1785392558376,"version":"3.55.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T00:00:00Z","timestamp":1626825600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003407","name":"Ministero dell\u2019Istruzione, dell\u2019Universit\u00e0 e della Ricerca","doi-asserted-by":"publisher","award":["PRIN project 2017YTWKWH"],"award-info":[{"award-number":["PRIN project 2017YTWKWH"]}],"id":[{"id":"10.13039\/501100003407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007514","name":"Universit\u00e0 di Pisa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100007514","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Endocrinol Invest"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteonecrosis of the jaw (ONJ) is a rare but very serious disease that can affect both jaws. It is defined as exposed bone in the maxillofacial region that does not heal within 8\u00a0weeks after a health care provider identification. ONJ can occur spontaneously or can be due to drugs like bisphosphonates (BPS) and anti-RANK agents, in patients with no history of external radiation therapy in the craniofacial region. Although in phase 3 trials of tyrosine kinase inhibitors (TKIs) used in thyroid cancer (TC) the ONJ was not reported among the most common side effects, several papers reported the association between ONJ and TKIs, both when they are used alone and in combination with a bisphosphonate. The appearance of an ONJ in a patient with metastatic radio-iodine refractory differentiated TC, treated with zoledronic acid and sorafenib, has put us in front of an important clinical challenge: when a ONJ occurred during TKIs treatment, it really worsens the patients\u2019 quality of life. We should consider that in the case of ONJ a TKI discontinuation becomes necessary, and this could lead to a progression of neoplastic disease. The most important aim of this review is to aware the endocrinologists\/oncologists dealing with TC to pay attention to this possible side effect of BPS and TKIs, especially when they are used in association. To significantly reduced the risk of ONJ, both preventive measures before initiating not only antiresorptive therapy but also antiangiogenic agents, and regular dental examinations during the treatment should always be proposed.<\/jats:p>","DOI":"10.1007\/s40618-021-01634-0","type":"journal-article","created":{"date-parts":[[2021,7,21]],"date-time":"2021-07-21T19:02:42Z","timestamp":1626894162000},"page":"2557-2566","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Osteonecrosis of the jaw: a rare but possible side effect in thyroid cancer patients treated with tyrosine-kinase inhibitors and bisphosphonates"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8773-3642","authenticated-orcid":false,"given":"L.","family":"Lorusso","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Pieruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gabriele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Nisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Viola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Molinaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Bottici","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Elisei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Agate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,21]]},"reference":[{"key":"1634_CR1","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","volume":"61","author":"RE Marx","year":"2003","unstructured":"Marx RE (2003) Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. J Oral Maxillofac Surg 61:1115\u20131117. https:\/\/doi.org\/10.1016\/S0278-2391(03)00720-1","journal-title":"J Oral Maxillofac Surg"},{"key":"1634_CR2","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1016\/j.joms.2004.02.004","volume":"62","author":"SL Ruggiero","year":"2004","unstructured":"Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL (2004) Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg 62:527\u2013534. https:\/\/doi.org\/10.1016\/j.joms.2004.02.004","journal-title":"J Oral Maxillofac Surg"},{"key":"1634_CR3","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1055\/s-0035-1558452","volume":"8","author":"RA Pollock","year":"2015","unstructured":"Pollock RA, Brown TW, Rubin DM (2015) \u201cPhossy Jaw\u201d and \u201cBis-phossy Jaw\u201d of the 19th and the 21st centuries: the diuturnity of John Walker and the friction Match. Craniomaxillofac Trauma Reconstr 8:262\u2013270. https:\/\/doi.org\/10.1055\/s-0035-1558452","journal-title":"Craniomaxillofac Trauma Reconstr"},{"key":"1634_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10006-012-0376-z","volume":"18","author":"C Jacobsen","year":"2014","unstructured":"Jacobsen C, Zemann W, Obwegeser JA, Gr\u00e4tz KW, Metzler P (2014) The phosphorous necrosis of the jaws and what can we learn from the past: a comparison of \u201cphossy\u201d and \u201cbisphossy\u201d jaw. Oral Maxillofac Surg 18:31\u201337. https:\/\/doi.org\/10.1007\/s10006-012-0376-z","journal-title":"Oral Maxillofac Surg"},{"key":"1634_CR5","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1016\/j.ctrv.2018.06.007","volume":"69","author":"S Otto","year":"2018","unstructured":"Otto S, Pautke C, Van den Wyngaert T, Niepel D, Schi\u00f8dt M (2018) Medication-related osteonecrosis of the jaw: prevention, diagnosis and management in patients with cancer and bone metastases. Cancer Treat Rev 69:177\u2013187. https:\/\/doi.org\/10.1016\/j.ctrv.2018.06.007","journal-title":"Cancer Treat Rev"},{"key":"1634_CR6","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","volume":"22","author":"S Khosla","year":"2007","unstructured":"Khosla S, Burr D, Cauley J, Dempster DW, Ebeling PR, Felsenberg D, Gagel RF, Gilsanz V, Guise T, Koka S et al (2007) Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 22:1479\u20131491. https:\/\/doi.org\/10.1359\/jbmr.0707onj","journal-title":"J Bone Miner Res"},{"key":"1634_CR7","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J, Goodday R, Aghaloo T, Mehrotra B, O\u2019Ryan F (2014) American association of oral and maxillofacial surgeons position paper on medication-related osteonecrosis of the jaw\u20142014 update. J Oral Maxillofac Surg 72:1938\u20131956. https:\/\/doi.org\/10.1016\/j.joms.2014.04.031","journal-title":"J Oral Maxillofac Surg"},{"key":"1634_CR8","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.bjoms.2009.08.030","volume":"48","author":"KH Taylor","year":"2010","unstructured":"Taylor KH, Middlefell LS, Mizen KD (2010) Osteonecrosis of the jaws induced by anti-RANK ligand therapy. Br J Oral Maxillofac Surg 48:221\u2013223. https:\/\/doi.org\/10.1016\/j.bjoms.2009.08.030","journal-title":"Br J Oral Maxillofac Surg"},{"key":"1634_CR9","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1007\/s10549-010-0933-9","volume":"122","author":"C Van Poznak","year":"2010","unstructured":"Van Poznak C (2010) Osteonecrosis of the jaw and bevacizumab therapy. Breast Cancer Res Treat 122:189\u2013191. https:\/\/doi.org\/10.1007\/s10549-010-0933-9","journal-title":"Breast Cancer Res Treat"},{"key":"1634_CR10","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1016\/j.bone.2008.08.132","volume":"44","author":"A Brunello","year":"2009","unstructured":"Brunello A, Saia G, Bedogni A, Scaglione D, Basso U (2009) Worsening of osteonecrosis of the jaw during treatment with sunitinib in a patient with metastatic renal cell carcinoma. Bone 44:173\u2013175. https:\/\/doi.org\/10.1016\/j.bone.2008.08.132","journal-title":"Bone"},{"key":"1634_CR11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.35.1551","author":"V Fusco","year":"2011","unstructured":"Fusco V, Galassi C, Berruti A, Ciuffreda L, Ortega C, Ciccone G, Angeli A, Bertetto O (2011) Osteonecrosis of the jaw after zoledronic acid and denosumab treatment. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2011.35.1551","journal-title":"J Clin Oncol"},{"key":"1634_CR12","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.clgc.2014.12.002","volume":"13","author":"V Fusco","year":"2015","unstructured":"Fusco V, Porta C, Saia G, Paglino C, Bettini G, Scoletta M, Bonacina R, Vescovi P, Merigo E, Lo Re G et al (2015) Osteonecrosis of the jaw in patients with metastatic renal cell cancer treated with bisphosphonates and targeted agents: results of an Italian multicenter study and review of the literature. Clin Genitourin Cancer 13:287\u2013294. https:\/\/doi.org\/10.1016\/j.clgc.2014.12.002","journal-title":"Clin Genitourin Cancer"},{"key":"1634_CR13","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA, Felsenberg D, McCauley LK, O\u2019Ryan F, Reid IR, Ruggiero SL, Taguchi A, Tetradis S et al (2015) Diagnosis and management of osteonecrosis of the jaw: a systematic review and international consensus. J Bone Miner Res 30:3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405","journal-title":"J Bone Miner Res"},{"key":"1634_CR14","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.3899\/jrheum.100221","volume":"38","author":"AA Khan","year":"2011","unstructured":"Khan AA, Rios LP, S\u00e1ndor GKB, Khan N, Peters E, Rahman MO, Clokie CML, Dore E, Dubois S (2011) Bisphosphonate-associated osteonecrosis of the jaw in Ontario: a survey of oral and maxillofacial surgeons. J Rheumatol 38:1396\u20131402. https:\/\/doi.org\/10.3899\/jrheum.100221","journal-title":"J Rheumatol"},{"key":"1634_CR15","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1002\/pds.3292","volume":"21","author":"P Tennis","year":"2012","unstructured":"Tennis P, Rothman KJ, Bohn RL, Tan H, Zavras A, Laskarides C, Calingaert B, Anthony MS (2012) Incidence of osteonecrosis of the jaw among users of bisphosphonates with selected cancers or osteoporosis. Pharmacoepidemiol Drug Saf 21:810\u2013817. https:\/\/doi.org\/10.1002\/pds.3292","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1634_CR16","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/S1470-2045(13)70174-8","volume":"14","author":"D Amadori","year":"2013","unstructured":"Amadori D, Aglietta M, Alessi B, Gianni L, Ibrahim T, Farina G, Gaion F, Bertoldo F, Santini D, Rondena R et al (2013) Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 14:663\u2013670. https:\/\/doi.org\/10.1016\/S1470-2045(13)70174-8","journal-title":"Lancet Oncol"},{"key":"1634_CR17","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1111\/j.1399-0012.2011.01527.x","volume":"26","author":"S Ganguly","year":"2012","unstructured":"Ganguly S, Divine CL, Aljitawi OS, Abhyankar S, Mcguirk JP, Graves L (2012) Prophylactic use of zoledronic acid to prevent early bone loss is safe and feasible in patients with acute myeloid leukemia undergoing allogeneic stem cell transplantation. Clin Transplant 26:447\u2013453. https:\/\/doi.org\/10.1111\/j.1399-0012.2011.01527.x","journal-title":"Clin Transplant"},{"key":"1634_CR18","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.breast.2012.09.012","volume":"22","author":"J Young","year":"2013","unstructured":"Young J, Nickman NA, Biskupiak JE, Barney RB, Gaffney DK, Namjoshi M, Brandt P (2013) Characterization of clinical course and usual care patterns in female metastatic breast cancer patients treated with zoledronic acid. Breast 22:495\u2013503. https:\/\/doi.org\/10.1016\/j.breast.2012.09.012","journal-title":"Breast"},{"key":"1634_CR19","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1620\/tjem.247.75","volume":"247","author":"T Shibahara","year":"2019","unstructured":"Shibahara T (2019) Antiresorptive agent-related osteonecrosis of the jaw (ARONJ): a twist of fate in the bone. Tohoku J Exp Med 247:75\u201386. https:\/\/doi.org\/10.1620\/tjem.247.75","journal-title":"Tohoku J Exp Med"},{"key":"1634_CR20","doi-asserted-by":"publisher","DOI":"10.1186\/1756-8722-5-56","author":"B Vincenzi","year":"2012","unstructured":"Vincenzi B, Napolitano A, Zoccoli A, Iuliani M, Pantano F, Papapietro N, Denaro V, Santini D, Tonini G (2012) Serum VEGF levels as predictive marker of bisphosphonate-related osteonecrosis of the jaw. J Hematol Oncol. https:\/\/doi.org\/10.1186\/1756-8722-5-56","journal-title":"J Hematol Oncol"},{"key":"1634_CR21","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jocd.2016.09.005","volume":"20","author":"AA Khan","year":"2017","unstructured":"Khan AA, Morrison A, Kendler DL, Rizzoli R, Hanley DA, Felsenberg D, McCauley LK, O\u2019Ryan F, Reid IR, Ruggiero SL et al (2017) Case-based review of osteonecrosis of the jaw (ONJ) and application of the international recommendations for management from the international task force on ONJ. J Clin Densitom 20:8\u201324. https:\/\/doi.org\/10.1016\/j.jocd.2016.09.005","journal-title":"J Clin Densitom"},{"key":"1634_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1159\/000201931","volume":"76","author":"C Christodoulou","year":"2009","unstructured":"Christodoulou C, Pervena A, Klouvas G, Galani E, Falagas ME, Tsakalos G, Visvikis A, Nikolakopoulou A, Acholos V, Karapanagiotidis G et al (2009) Combination of bisphosphonates and antiangiogenic factors induces osteonecrosis of the jaw more frequently than bisphosphonates alone. Oncology 76:209\u2013211. https:\/\/doi.org\/10.1159\/000201931","journal-title":"Oncology"},{"key":"1634_CR23","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.ejca.2021.03.046","volume":"150","author":"L Wenchao","year":"2021","unstructured":"Wenchao L, Qixiang G, Zhuo M, Lihong L, Zhao Z (2021) Lenvatinib and osteonecrosis of the jaw: a pharmacovigilance study. Eur J Cancer 150:211\u2013213","journal-title":"Eur J Cancer"},{"key":"1634_CR24","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1111\/odi.12966","volume":"25","author":"SY Jung","year":"2019","unstructured":"Jung SY, Suh HS, Park JW, Kwon JW (2019) Drug holiday patterns and bisphosphonate-related osteonecrosis of the jaw. Oral Dis 25:471\u2013480. https:\/\/doi.org\/10.1111\/odi.12966","journal-title":"Oral Dis"},{"key":"1634_CR25","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1007\/s00520-017-3903-5","volume":"26","author":"T van Cann","year":"2018","unstructured":"van Cann T, Loyson T, Verbiest A, Clement PM, Bechter O, Willems L, Spriet I, Coropciuc R, Politis C, Vandeweyer RO et al (2018) Incidence of medication-related osteonecrosis of the jaw in patients treated with both bone resorption inhibitors and vascular endothelial growth factor receptor tyrosine kinase inhibitors. Support Care Cancer 26:869\u2013878. https:\/\/doi.org\/10.1007\/s00520-017-3903-5","journal-title":"Support Care Cancer"},{"key":"1634_CR26","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bjoms.2014.09.001","volume":"53","author":"S Fedele","year":"2015","unstructured":"Fedele S, Bedogni G, Scoletta M, Favia G, Colella G, Agrillo A, Bettini G, Di Fede O, Oteri G, Fusco V et al (2015) Up to a quarter of patients with osteonecrosis of the jaw associated with antiresorptive agents remain undiagnosed. Br J Oral Maxillofac Surg 53:13\u201317. https:\/\/doi.org\/10.1016\/j.bjoms.2014.09.001","journal-title":"Br J Oral Maxillofac Surg"},{"key":"1634_CR27","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.oooo.2013.10.010","volume":"117","author":"M Schiodt","year":"2014","unstructured":"Schiodt M, Reibel J, Oturai P, Kofod T (2014) Comparison of nonexposed and exposed bisphosphonate-induced osteonecrosis of the jaws: a retrospective analysis from the Copenhagen cohort and a proposal for an updated classification system. Oral Surg Oral Med Oral Pathol Oral Radiol 117:204\u2013213. https:\/\/doi.org\/10.1016\/j.oooo.2013.10.010","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1634_CR28","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.oraloncology.2012.02.009","volume":"48","author":"JV Bagan","year":"2012","unstructured":"Bagan JV, Hens-Aumente E, Leopoldo-Rodado M, Poveda-Roda R, Bagan L (2012) Bisphosphonate-related osteonecrosis of the jaws: study of the staging system in a series of clinical cases. Oral Oncol 48:753\u2013757. https:\/\/doi.org\/10.1016\/j.oraloncology.2012.02.009","journal-title":"Oral Oncol"},{"key":"1634_CR29","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bdj.2017.1001","author":"H Devlin","year":"2018","unstructured":"Devlin H, Greenwall-Cohen J, Benton J, Goodwin TL, Littlewood A, Horner K (2018) Detecting the earliest radiological signs of bisphosphonate-related osteonecrosis. Br Dent J. https:\/\/doi.org\/10.1038\/sj.bdj.2017.1001","journal-title":"Br Dent J"},{"key":"1634_CR30","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1016\/j.oooo.2016.06.002","volume":"122","author":"T Taniguchi","year":"2016","unstructured":"Taniguchi T, Ariji Y, Nozawa M, Naitoh M, Kuroiwa Y, Kurita K, Ariji E (2016) Computed tomographic assessment of early changes of the mandible in bisphosphonate-treated patients. Oral Surg Oral Med Oral Pathol Oral Radiol 122:362\u2013372. https:\/\/doi.org\/10.1016\/j.oooo.2016.06.002","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1634_CR31","doi-asserted-by":"publisher","first-page":"924","DOI":"10.1016\/j.jcms.2014.01.012","volume":"42","author":"H Hamada","year":"2014","unstructured":"Hamada H, Matsuo A, Koizumi T, Satomi T, Chikazu D (2014) A simple evaluation method for early detection of bisphosphonate-related osteonecrosis of the mandible using computed tomography. J Cranio-Maxillofac Surg 42:924\u2013929. https:\/\/doi.org\/10.1016\/j.jcms.2014.01.012","journal-title":"J Cranio-Maxillofac Surg"},{"key":"1634_CR32","first-page":"E114","volume":"62","author":"E Iwata","year":"2016","unstructured":"Iwata E, Akashi M, Kishimoto M, Kusumoto J, Hasegawa T, Furudoi S, Komori T (2016) Meaning and limitation of cortical bone width measurement with DentaScan in medication-related osteonecrosis of the jaws. Kobe J Med Sci 62:E114\u2013E119","journal-title":"Kobe J Med Sci"},{"key":"1634_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1093\/annonc\/mdn554","volume":"20","author":"MA Dimopoulos","year":"2009","unstructured":"Dimopoulos MA, Kastritis E, Bamia C, Melakopoulos I, Gika D, Roussou M, Migkou M, Eleftherakis-Papaiakovou E, Christoulas D, Terpos E et al (2009) Reduction of osteonecrosis of the jaw (ONJ) after implementation of preventive measures in patients with multiple myeloma treated with zoledronic acid. Ann Oncol 20:117\u2013120. https:\/\/doi.org\/10.1093\/annonc\/mdn554","journal-title":"Ann Oncol"},{"key":"1634_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1093\/annonc\/mdn526","volume":"20","author":"CI Ripamonti","year":"2009","unstructured":"Ripamonti CI, Maniezzo M, Campa T, Fagnoni E, Brunelli C, Saibene G, Bareggi C, Ascani L, Cislaghi E (2009) Decreased occurrence of osteonecrosis of the jaw after implementation of dental preventive measures in solid tumour patients with bone metastases treated with bisphosphonates. The experience of the National Cancer Institute of Milan. Ann Oncol 20:137\u2013145. https:\/\/doi.org\/10.1093\/annonc\/mdn526","journal-title":"Ann Oncol"},{"key":"1634_CR35","first-page":"b147","volume":"77","author":"R Bonacina","year":"2011","unstructured":"Bonacina R, Mariani U, Villa F, Villa A (2011) Preventive strategies and clinical implications for bisphosphonate-related osteonecrosis of the Jaw: a review of 282 patients. J Can Dent Assoc 77:b147","journal-title":"J Can Dent Assoc"},{"key":"1634_CR36","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.otc.2008.07.001","volume":"41","author":"M Xing","year":"2008","unstructured":"Xing M (2008) Recent advances in molecular biology of thyroid cancer and their clinical implications. Otolaryngol Clin N Am 41:1135\u20131146. https:\/\/doi.org\/10.1016\/j.otc.2008.07.001","journal-title":"Otolaryngol Clin N Am"},{"key":"1634_CR37","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, De La Fouchardiere C, Pacini F, Paschke R, Shong YK et al (2014) Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. The Lancet 384:319\u2013328. https:\/\/doi.org\/10.1016\/S0140-6736(14)60421-9","journal-title":"The Lancet"},{"key":"1634_CR38","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/nejmoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger M, Tahara M, Wirth LJ, Robinson B, Brose MS, Elisei R, Habra MA, Newbold K, Shah MH, Hoff AO et al (2015) Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl J Med 372:621\u2013630. https:\/\/doi.org\/10.1056\/nejmoa1406470","journal-title":"N Engl J Med"},{"key":"1634_CR39","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1200\/JCO.2011.35.5040","volume":"30","author":"SA Wells","year":"2012","unstructured":"Wells SA, Robinson BG, Gagel RF, Dralle H, Fagin JA, Santoro M, Baudin E, Elisei R, Jarzab B, Vasselli JR et al (2012) Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 30:134\u2013141. https:\/\/doi.org\/10.1200\/JCO.2011.35.5040","journal-title":"J Clin Oncol"},{"key":"1634_CR40","doi-asserted-by":"publisher","first-page":"3639","DOI":"10.1200\/JCO.2012.48.4659","volume":"31","author":"R Elisei","year":"2013","unstructured":"Elisei R, Schlumberger MJ, M\u00fcller SP, Sch\u00f6ffski P, Brose MS, Shah MH, Licitra L, Jarzab B, Medvedev V, Kreissl MC et al (2013) Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 31:3639\u20133646. https:\/\/doi.org\/10.1200\/JCO.2012.48.4659","journal-title":"J Clin Oncol"},{"key":"1634_CR41","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1016\/j.ijom.2019.07.010","volume":"48","author":"R Mauceri","year":"2019","unstructured":"Mauceri R, Panzarella V, Morreale I, Campisi G (2019) Medication-related osteonecrosis of the jaw in a cancer patient receiving lenvatinib. Int J Oral Maxillofac Surg 48:1530\u20131532. https:\/\/doi.org\/10.1016\/j.ijom.2019.07.010","journal-title":"Int J Oral Maxillofac Surg"},{"key":"1634_CR42","doi-asserted-by":"publisher","first-page":"S69","DOI":"10.5301\/tj.5000504","volume":"102","author":"F Garuti","year":"2016","unstructured":"Garuti F, Camelli V, Spinardi L, Bucci L, Trevisani F (2016) Osteonecrosis of the jaw during sorafenib therapy for hepatocellular carcinoma. Tumori 102:S69\u2013S70. https:\/\/doi.org\/10.5301\/tj.5000504","journal-title":"Tumori"},{"key":"1634_CR43","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.23.4252","author":"M Guillet","year":"2010","unstructured":"Guillet M, Walter T, Scoazec JY, Vial T, Lombard-Bohas C, Dumortier J (2010) Sorafenib-induced bilateral osteonecrosis of femoral heads. J Clin Oncol. https:\/\/doi.org\/10.1200\/JCO.2009.23.4252","journal-title":"J Clin Oncol"},{"key":"1634_CR44","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1016\/j.joms.2013.03.019","volume":"71","author":"T Smidt-Hansen","year":"2013","unstructured":"Smidt-Hansen T, Folkmar TB, Fode K, Agerbaek M, Donskov F (2013) Combination of zoledronic acid and targeted therapy is active but may induce osteonecrosis of the jaw in patients with metastatic renal cell carcinoma. J Oral Maxillofac Surg 71:1532\u20131540. https:\/\/doi.org\/10.1016\/j.joms.2013.03.019","journal-title":"J Oral Maxillofac Surg"},{"key":"1634_CR45","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1038\/bjc.2012.385","volume":"107","author":"B Beuselinck","year":"2012","unstructured":"Beuselinck B, Wolter P, Karadimou A, Elaidi R, Dumez H, Rogiers A, Van Cann T, Willems L, Body JJ, Berkers J et al (2012) Concomitant oral tyrosine kinase inhibitors and bisphosphonates in advanced renal cell carcinoma with bone metastases. Br J Cancer 107:1665\u20131671. https:\/\/doi.org\/10.1038\/bjc.2012.385","journal-title":"Br J Cancer"},{"key":"1634_CR46","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1111\/adj.12254","volume":"60","author":"R Marino","year":"2015","unstructured":"Marino R, Orlandi F, Arecco F, Gandolfo S, Pentenero M (2015) Osteonecrosis of the jaw in a patient receiving cabozantinib. Aust Dent J 60:528\u2013531. https:\/\/doi.org\/10.1111\/adj.12254","journal-title":"Aust Dent J"},{"key":"1634_CR47","doi-asserted-by":"publisher","DOI":"10.1155\/2020\/8093293","author":"F Bennardo","year":"2020","unstructured":"Bennardo F, Buffone C, Muraca D, Antonelli A, Giudice A (2020) Medication-related osteonecrosis of the jaw with spontaneous hemimaxilla exfoliation: report of a case in metastatic renal cancer patient under multidrug therapy. Case Rep Med. https:\/\/doi.org\/10.1155\/2020\/8093293","journal-title":"Case Rep Med"},{"key":"1634_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/thy.2015.0020","volume":"26","author":"BR Haugen","year":"2016","unstructured":"Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M et al (2016) 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association Guidelines Task Force on thyroid nodules and differentiated thyroid cancer. Thyroid 26:1\u2013133. https:\/\/doi.org\/10.1089\/thy.2015.0020","journal-title":"Thyroid"},{"key":"1634_CR49","doi-asserted-by":"publisher","first-page":"e253","DOI":"10.7417\/T.2017.2015","volume":"168","author":"M Capocci","year":"2017","unstructured":"Capocci M, Romeo U, Guerra F, Mannocci A, Tenore G, Annibali S, Ottolenghi L (2017) Medication-related osteonecrosis of the jaws (MRONJ) and quality of life evaluation: a pilot study. Clin Ter 168:e253\u2013e257. https:\/\/doi.org\/10.7417\/T.2017.2015","journal-title":"Clin Ter"},{"key":"1634_CR50","doi-asserted-by":"publisher","first-page":"e257","DOI":"10.1016\/j.oooo.2017.08.003","volume":"124","author":"V Patel","year":"2017","unstructured":"Patel V, Sproat C, Kwok J, Tanna N (2017) Axitinib-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 124:e257\u2013e260. https:\/\/doi.org\/10.1016\/j.oooo.2017.08.003","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1634_CR51","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/6621937","author":"M Okubo-Sato","year":"2021","unstructured":"Okubo-Sato M, Yamagata K, Fukuzawa S, Terada K, Uchida F, Ishibashi-Kanno N, Bukawa H (2021) Medication-related osteonecrosis of the jaw spontaneously occurred in a patient with chronic myelogenous leukemia only by imatinib: a report of a rare case. Case Reports in Dentistry. https:\/\/doi.org\/10.1155\/2021\/6621937","journal-title":"Case Reports in Dentistry"},{"key":"1634_CR52","doi-asserted-by":"publisher","first-page":"e157","DOI":"10.1016\/j.oooo.2020.10.005","volume":"131","author":"L Gupta","year":"2021","unstructured":"Gupta L, Dholam K, Janghel Y, Gurav SV (2021) Osteonecrosis of the jaw associated with imatinib therapy in myeloproliferative neoplasm: a rare case report. Oral Surg Oral Med Oral Pathol Oral Radiol 131:e157\u2013e162. https:\/\/doi.org\/10.1016\/j.oooo.2020.10.005","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1634_CR53","doi-asserted-by":"publisher","first-page":"120","DOI":"10.5125\/JKAOMS.2017.43.2.120","volume":"43","author":"M Viviano","year":"2017","unstructured":"Viviano M, Rossi M, Cocca S (2017) A rare case of osteonecrosis of the jaw related to imatinib. J Korean Assoc Oral Maxillofac Surg 43:120\u2013124. https:\/\/doi.org\/10.5125\/JKAOMS.2017.43.2.120","journal-title":"J Korean Assoc Oral Maxillofac Surg"},{"key":"1634_CR54","doi-asserted-by":"publisher","first-page":"182","DOI":"10.4103\/jrpp.jrpp_17_36","volume":"6","author":"F Ashrafi","year":"2017","unstructured":"Ashrafi F, Derakhshandeh A, Movahedian B, Moghaddas A (2017) Osteonecrosis of the jaws in patient received bisphosphonates and sunitinib separately: a case report. J Res Pharm Pract 6:182. https:\/\/doi.org\/10.4103\/jrpp.jrpp_17_36","journal-title":"J Res Pharm Pract"},{"key":"1634_CR55","first-page":"952","volume":"16","author":"A Agrillo","year":"2012","unstructured":"Agrillo A, Siniscalchi EN, Facchini A, Filiaci F, Ungari C (2012) Osteonecrosis of the jaws in patients assuming bisphosphonates and sunitinib: two case reports. Eur Rev Med Pharmacol Sci 16:952\u2013957","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"1634_CR56","doi-asserted-by":"publisher","DOI":"10.1016\/j.tripleo.2011.06.023","author":"Y Fleissig","year":"2012","unstructured":"Fleissig Y, Regev E, Lehman H (2012) Sunitinib related osteonecrosis of jaw: a case report. Oral Surg Oral Med Oral Pathol Oral Radiol. https:\/\/doi.org\/10.1016\/j.tripleo.2011.06.023","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1634_CR57","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/j.tripleo.2011.08.024","volume":"113","author":"O Nicolatou-Galitis","year":"2012","unstructured":"Nicolatou-Galitis O, Migkou M, Psyrri A, Bamias A, Pectasides D, Economopoulos T, Raber-Durlacher JE, Dimitriadis G, Dimopoulos MA (2012) Gingival bleeding and jaw bone necrosis in patients with metastatic renal cell carcinoma receiving sunitinib: report of 2 cases with clinical implications. Oral Surg Oral Med Oral Pathol Oral Radiol 113:234\u2013238. https:\/\/doi.org\/10.1016\/j.tripleo.2011.08.024","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"1634_CR58","doi-asserted-by":"publisher","first-page":"463","DOI":"10.1016\/j.tripleo.2010.04.049","volume":"110","author":"S Hoefert","year":"2010","unstructured":"Hoefert S, Eufinger H (2010) Sunitinib may raise the risk of bisphosphonate-related osteonecrosis of the jaw: presentation of three cases. Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol 110:463\u2013469. https:\/\/doi.org\/10.1016\/j.tripleo.2010.04.049","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endodontol"},{"key":"1634_CR59","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1159\/000313680","volume":"33","author":"G Bozas","year":"2010","unstructured":"Bozas G, Roy A, Ramasamy V, Maraveyas A (2010) Osteonecrosis of the jaw after a single bisphosphonate infusion in a patient with metastatic renal cancer treated with sunitinib. Onkologie 33:321\u2013323. https:\/\/doi.org\/10.1159\/000313680","journal-title":"Onkologie"},{"key":"1634_CR60","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1007\/s10006-010-0224-y","volume":"15","author":"FP Koch","year":"2011","unstructured":"Koch FP, Walter C, Hansen T, J\u00e4ger E, Wagner W (2011) Osteonecrosis of the jaw related to sunitinib. Oral Maxillofac Surg 15:63\u201366. https:\/\/doi.org\/10.1007\/s10006-010-0224-y","journal-title":"Oral Maxillofac Surg"},{"key":"1634_CR61","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1016\/j.bjoms.2019.05.017","volume":"57","author":"S Akkach","year":"2019","unstructured":"Akkach S, Shukla L, Morgan D (2019) Everolimus-induced osteonecrosis of the jaw in the absence of bisphosphonates: a case report. Br J Oral Maxillofac Surg 57:688\u2013690. https:\/\/doi.org\/10.1016\/j.bjoms.2019.05.017","journal-title":"Br J Oral Maxillofac Surg"},{"key":"1634_CR62","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3892\/mco.2016.1100","volume":"6","author":"D Yamamoto","year":"2017","unstructured":"Yamamoto D, Tsubota Y, Utsunomiya T, Sueoka N, Ueda A, Endo K, Yoshikawa K, Kon M (2017) Osteonecrosis of the jaw associated with everolimus: a case report. Mol Clin Oncol 6:255\u2013257. https:\/\/doi.org\/10.3892\/mco.2016.1100","journal-title":"Mol Clin Oncol"},{"key":"1634_CR63","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1111\/tbj.12808","volume":"23","author":"C Omarini","year":"2017","unstructured":"Omarini C, Filieri ME, Depenni R, Grizzi G, Cascinu S, Piacentini F (2017) Osteonecrosis of the jaw in a breast cancer patient treated with everolimus and a single dose of zoledronic acid. Breast J 23:610\u2013611","journal-title":"Breast J"},{"issue":"Suppl 2","key":"1634_CR64","first-page":"20","volume":"4","author":"F Giancola","year":"2013","unstructured":"Giancola F, Campisi G, Lo-Russo L, Muzio LL, Di Fede O (2013) Osteonecrosis of the jaw related to everolimus and bisphosphonate: a unique case report? Ann Stomatol (Roma) 4(Suppl 2):20","journal-title":"Ann Stomatol (Roma)"},{"key":"1634_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.bjoms.2013.09.008","author":"DW Kim","year":"2013","unstructured":"Kim DW, Jung YS, Park HS, Jung HD (2013) Osteonecrosis of the jaw related to everolimus: a case report. Br J Oral Maxillofac Surg. https:\/\/doi.org\/10.1016\/j.bjoms.2013.09.008","journal-title":"Br J Oral Maxillofac Surg"}],"container-title":["Journal of Endocrinological Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01634-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40618-021-01634-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40618-021-01634-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,6]],"date-time":"2021-11-06T21:16:45Z","timestamp":1636233405000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40618-021-01634-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,21]]},"references-count":65,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1634"],"URL":"https:\/\/doi.org\/10.1007\/s40618-021-01634-0","relation":{},"ISSN":["1720-8386"],"issn-type":[{"value":"1720-8386","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,21]]},"assertion":[{"value":"18 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Lorusso Loredana, Pieruzzi Letizia, Gabriele Mario, Nisi Marco, Viola David, Molinaro Eleonora, Bottici Valeria, and Agate Laura have nothing to disclose and no competing financial interests exist. Elisei Rossella is consultant for Bayer, EISAI, Loxo, Ipsen, Lilly.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The patient gave his consent to participate and to publish his clinical data.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate and for publication"}}]}}